Cite

    Bartko, J., Schoergenhofer, C., Schwameis, M., Firbas, C., Beliveau, M., Chang, C., Marier, J., Nix, D., Gilbert, J. C., Panicker, S., & Jilma, B. (2018). a Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. Clinical pharmacology & therapeutics, 104(4), 655–663. http://access.bl.uk/ark:/81055/vdc_100069103479.0x000059